Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Venetoclax

Review the clinical trials studying venetoclax on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-50 of 157

Assessing Minimal Residual Disease to Minimize Exposure in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Who Have Been Treated with Venetoclax, Veneto-STOP Study
Status: Active
Location: 7 locations
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
Status: Active
Location: 7 locations
Zanubrutinib and Venetoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Location: 7 locations
A Study of Azacitidine and Venetoclax versus a Stem Cell Transplant in People 65 Years and Older with Acute Myeloid Leukemia
Status: Active
Location: 7 locations
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
Status: Active
Location: 6 locations
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Status: Active
Location: 8 locations
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active
Location: 6 locations
Revumenib, Azacitidine, and Venetoclax for the Treatment of Pediatric and Young Adult Patients with Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage
Status: Active
Location: 6 locations
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Status: Active
Location: 10 locations
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Status: Active
Location: 5 locations
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Status: Active
Location: 5 locations
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
Status: Active
Location: 5 locations
Revumenib and Venetoclax for the Treatment of Patients with Acute Myeloid Leukemia with Measurable Residual Disease
Status: Active
Location: 4 locations
Venetoclax and Dexamethasone in the Treatment of Relapsed or Refractory AL Amyloidosis
Status: Active
Location: 4 locations
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
Status: Active
Location: 4 locations
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Status: Active
Location: 4 locations
Testing the Combination of an Anti-Cancer Drug, Iadademstat, with Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
Status: Active
Location: 4 locations
Tagraxofusp-erzs, Azacitidine and Venetoclax for the Treatment of Untreated, Relapsed, or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active
Location: 4 locations
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period.
Status: Active
Location: 5 locations
Selinexor, Venetoclax, and Dexamethasone for the Treatment of t(11;14)-Positive Relapsed or Refractory Multiple Myeloma, SELVEDge Trial
Status: Active
Location: 3 locations
Venetoclax and Pirtobrutinib for the Treatment of Previously Treated Waldenstrom Macroglobulinemia
Status: Active
Location: 3 locations
MRD Adapted Therapy with Venetoclax, Obinutuzumab, and Acalabrutinib for the Treatment of High- or Intermediate-Risk Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Location: 3 locations
Adding Dasatinib or Venetoclax to Standard Chemotherapy for the Treatment in Children with T-Cell Acute Lymphoblastic Leukemia or T-Cell Lymphoma or Mixed Phenotype Acute Leukemia, the SJALL23T Trial
Status: Active
Location: 3 locations
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: 3 locations
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies
Status: Active
Location: 3 locations